WAIKOLOA, Hawaii — In this Healio Video Perspective from Retina 2026, Sharon Fekrat, MD, FACS, FASRS, of Duke University, discusses the current management of diabetic macular edema and diabetic retinopathy.
Fekrat examined second-generation anti-VEGF therapies, including Eylea HD (aflibercept 8 mg, Regeneron) and Vabysmo (faricimab-svoa, Genentech).
She also shared some take-home points.
“Early intervention in vision-threatening diabetic macular edema does prevent visual acuity loss,” Fekrat said. “Eyes with good vision and DME can be observed until they begin to worsen.”